UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival

British journal of haematology, 2020-08, Vol.190 (3), p.394-404

2020

Volltextzugriff (PDF)

Advances in treatment of elderly primary central nervous system lymphoma

British journal of haematology, 2022-02, Vol.196 (3), p.473-487

2022

Volltextzugriff (PDF)

Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity

British journal of haematology, 2019-10, Vol.187 (2), p.185-194

2019

Volltextzugriff (PDF)

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice

British journal of haematology, 2020-06, Vol.189 (5), p.879-887

2020

Volltextzugriff (PDF)

Guideline for the treatment of chronic lymphocytic leukaemia

British journal of haematology, 2022-06, Vol.197 (5), p.544-557

2022

Volltextzugriff (PDF)

Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study

British journal of haematology, 2023-07, Vol.202 (1), p.48-53

2023

Volltextzugriff (PDF)

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data

British journal of haematology, 2022-02, Vol.196 (4), p.932-938

2022

Volltextzugriff (PDF)

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

British journal of haematology, 2022-01, Vol.196 (1), p.70-78

2022

Volltextzugriff (PDF)

Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysis

British journal of haematology, 2019-03, Vol.184 (6), p.957-968

2019

Volltextzugriff (PDF)

Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom

British journal of haematology, 2021-11, Vol.195 (4), p.561-570

2021

Volltextzugriff (PDF)

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis

British journal of haematology, 2021-07, Vol.194 (2), p.365-377

2021

Volltextzugriff (PDF)

Interpretation of retrospective data evaluating high‐dose methotrexate as central nervous system prophylaxis in diffuse large B‐cell lymphoma; caution required

American journal of hematology, 2021-09, Vol.96 (9), p.E338-E339

2021

Volltextzugriff (PDF)

Extended follow‐up of CD4+ T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine

Hematological oncology, 2021-02, Vol.39 (1), p.137-140

2021

Volltextzugriff (PDF)

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R‐CHOP

British journal of haematology, 2019-08, Vol.186 (4), p.e94-e98

2019

Volltextzugriff (PDF)

PB1930: EPIC: A NON‐INTERVENTIONAL, OBSERVATIONAL STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FIRST‐LINE ACALABRUTINIB THROUGH THE UK EARLY ACCESS PROGRAMME. INTERIM ANALYSIS UP TO 24 MONTHS

HemaSphere, 2023-08, Vol.7 (S3), p.e980300b-n/a

2023

Volltextzugriff (PDF)

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience

Blood advances, 2024-02, Vol.8 (4), p.878-888

2024

Volltextzugriff (PDF)

DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters?

Cancers, 2019-09, Vol.11 (10), p.1424

2019

Volltextzugriff (PDF)

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax

EJHaem, 2020-11, Vol.1 (2), p.418-419

2020

Volltextzugriff (PDF)

Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

British journal of haematology, 2020-06, Vol.189 (6), p.1064-1073

2020

Volltextzugriff (PDF)

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial

Blood advances, 2021-10, Vol.5 (20), p.4073-4082

2021

Volltextzugriff (PDF)

First‐line use of rituximab correlates with increased overall survival in late post‐transplant lymphoproliferative disorders: retrospective, single‐centre study

European journal of haematology, 2017-01, Vol.98 (1), p.38-43

2017

Volltextzugriff (PDF)

Response to letter

Journal of travel medicine, 2014-05, Vol.21 (3), p.220-221

2014

Volltextzugriff (PDF)

Asymptomatic Schistosoma haematobium infection in a traveler with negative urine microscopy and late seroconversion presumably linked to artemisinin

Journal of travel medicine, 2013-09, Vol.20 (5), p.326-328

2013

Volltextzugriff (PDF)

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy

Journal of personalized medicine, 2023-07, Vol.13 (7), p.1182

2023

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(51)
Berichte
(2)

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(29)
Hematology
(24)
Humans
(24)
Aged
(13)
Adult
(12)
Male
(12)
Female
(10)
Lymphoma
(10)
Middle Aged
(10)
Retrospective Studies
(10)
Aged, 80 And Over
(9)
Patients
(9)
Rituximab
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Central Nervous System
(7)
Immunotherapy
(7)
Monoclonal Antibodies
(6)
Nervous System
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival

Advances in treatment of elderly primary central nervous system lymphoma

Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice

Guideline for the treatment of chronic lymphocytic leukaemia

Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysis

Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis

Interpretation of retrospective data evaluating high‐dose methotrexate as central nervous system prophylaxis in diffuse large B‐cell lymphoma; caution required

Extended follow‐up of CD4+ T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R‐CHOP

PB1930: EPIC: A NON‐INTERVENTIONAL, OBSERVATIONAL STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FIRST‐LINE ACALABRUTINIB THROUGH THE UK EARLY ACCESS PROGRAMME. INTERIM ANALYSIS UP TO 24 MONTHS

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience

DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters?

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax

Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial

First‐line use of rituximab correlates with increased overall survival in late post‐transplant lymphoproliferative disorders: retrospective, single‐centre study

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma

Response to letter

Asymptomatic Schistosoma haematobium infection in a traveler with negative urine microscopy and late seroconversion presumably linked to artemisinin

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy

Suchergebnisse filtern